

- Breast disease (*Continued*)
inflammatory, 1046-1048
duct ectasia as, 1046-1047, 1047f
fat necrosis as, 1047
lymphocytic mastopathy as, 1047
mastitis as
acute, 1046
granulomatous, 1047-1048
periductal, 1046
lymphomas as, 1070
male, 1066
carcinoma as, 1066
gynecomastia as, 1049-1050, 1050f
metastases as, 1066
stromal tumors as, 1068-1070, 1070b
benign, 1070
fibroadenoma as, 1069, 1069f
malignant, 1070
phyllodes tumor as, 1069-1070, 1070f
Breast milk, 1046
Breast pain, 1045
Breast tissue, accessory axillary, 1045
Breastfeeding, and breast cancer, 1053
Brenner tumors, 1028, 1028f
Bridging veins, in subdural hematoma, 1262
Broad-spectrum antibiotics, 583
Brodie abscess, 1195b
"Broken heart syndrome." *See* Takotsubo cardiomyopathy.
Bronchiectasis, 674t, 683-684, 683b-684b, 684f
Bronchioles, 670
Bronchiolitis, 674t, 707b
Bronchiolitis obliterans organizing pneumonia, 687
Bronchopulmonary dysplasia (BPD), in neonatal respiratory distress syndrome, 459
Brown atrophy, 37
Brown tumor, 1102b-1103b, 1191b-1192b, 1192f
Brunn nests, 963-964
Bubonic plague, 370b
Budd-Chiari syndrome, 863-864, 863b, 864f
Buerger disease. *See* Thromboangiitis obliterans.
Bulbar conjunctiva, 1322-1323
Bulimia, 435
Bulla, 1143t
Bullous pemphigoid, 1170, 1170b, 1170f, 1171f
Bundle of His, 525
Buphthalmos, 1341b
Burkitt lymphoma, 591t, 597, 597b-598b, 598f
Epstein-Barr virus and, 327, 327f, 362
Burns, thermal, 426-427
"Buttonhole" stenoses, 929
Byproduct
sulfur dioxide as, 409
xenobiotics as, 407
- C**
C chemokines, 87
C1 inhibitor (C1 INH), in complement system, 89
C3 convertase, 88
C3a, 88-89
C3b, 88-89, 350
C4a, 89
C5 convertase, 88
C5a, 88-89
C-21 hydroxylase deficiency, 1127f, 1128
Cachectin, in cachexia, 330
Cachexia, 86, 435
cancer, mechanisms of, 435f
due to cancer, 330
CACNA1S, mutations of, 1246
Cadherins, 12
Cadmium
as carcinogen, 278t
in environmental pollution, 413
Café au lait spots, 1317
Caisson disease, 128
Calcific band keratopathy, 1325
Calcification(s)
of breast, 1046
pathologic, 65-66, 65b
Calciophylaxis, 1104
Calcitonin, 1083
Calcium
blood, interaction of PTH in regulation of, 440
reabsorption, in kidney, stimulation of, 440
Calcium homeostasis
loss of, cell injury due to, 46-47, 47f
vitamin D in, 439-440
Calcium influx, cell injury due to, 46-47, 47f
Calcium oxalate stones, 951-952, 951t
Calcium pyrophosphate crystal deposition disease, 1217
Call-Exner bodies, in granulosa cell tumors, 1032b
Calor, 71, 93
Caloric restriction, in cellular aging, 68
Calyx(ces), 934f, 951f
Camptomelic dysplasia, 1184t
Canalicular cholestasis, 854-855
Canals of Hering, 102
Cancer
alcohol consumption and, 277
benign tumors and, 267-275, 274b-275b, 274t
cachexia due to, 330
carcinogenic agents in, 321-338
chemical, 322, 322f, 323t, 324b
direct-acting, 322
indirect-acting, 323-324
microbial, 325-329
radiation as, 324-325
categorization of undifferentiated, 334, 334f
cell cycle and inhibitors in, 289t
cell-like properties of, 303-305
characteristics of, 267-275, 274b-275b, 274t
differentiation and anaplasia as, 268-271, 269f, 274t
local invasion as, 271-272, 274t
metastasis as, 272-275
chronic inflammation and, 279, 279t
classification of, 336f
clonal expansion of, 280
defined, 266
detection of molecules of prognostic or therapeutic significance in, 334
development of, 281f
diet and, 277, 448-449
enabling inflammation and, 315-316
epidemiology of, 275-280, 280b
acquired predisposing conditions in, 278-279
age in, 278
environmental factors in, 276-278
genetic predisposition in, 279-280
geographic variation in, 277f
global impact of, 275-276
Cancer (*Continued*)
incidence in, 275, 276f
grading and staging of, 332
growth factor signaling pathways in, 285f
hereditary predisposition to, 335
host defense, evasion of, 310-314
antitumor effector mechanisms in, 312
immune surveillance and escape as, 310, 312-314, 314b
tumor antigens in, 310-312, 311f
laboratory diagnosis of, 332-338, 338b
molecular basis of, 280-321
angiogenesis in, 283, 305-306, 306b, 316
cellular and molecular hallmarks of, 280-283, 283f
chromosomal changes in, 316-319
chromosomal translocations in, 316-317
dysregulation of cancer-associated genes in, 316-320
epigenetic changes in, 319-320
evasion of apoptosis in, 283
gene amplification in, 318
genetic lesions in, 319b
genomic instability in, 283, 314-315, 315b
immunodeficiency states and, 279
invasion and metastasis in, 283, 310b, 316
local and hormonal effects of, 330
microRNAs (miRNAs) in, 320
as multistep, 320-321
mutations in, 281
noncoding RNAs and, 320
oncogenes in, 283-290, 284t
regulatory genes in, 280
tumor suppressor genes in, 290-300, 291t
Warburg effects in, 300-301
molecular profiles of, 335-336
nomenclature for, 266-267
obesity and, 277-278, 447f, 448
occupational, 278t
paraneoplastic syndromes due to, 330-332, 331t
precursor lesions and, 279
promoting inflammation and, 283
reproductive history and, 278
risks from exposures to radiation, 431-432
tumor markers for, 337-338
Cancer immunoeediting, 310
Cancer stem cells, 281
Cancer-testis antigens, 311
Candida albicans, 386
Candida esophagitis, 386b-387b, 387f
Candida vaginitis, 386b-387b
Candidiasis, 386-387, 386b-387b, 387f
in AIDS, 253
cutaneous, 386b-387b
invasive, 386b-387b
Canker sores, 728, 728f
Capillaries, structure and function of, 485
Capillary hemangiomas, 516
Capillary telangiectasias, 1271b
Carbon dioxide (CO₂), in greenhouse effect, 405
Carbon monoxide
as air pollutant, 409, 409b
CNS toxicity of, 1305
Carbon tetrachloride, occupational health risks, 413
Carbonic anhydrase 2 (CA2) gene, 1186
Carbuncle, 364b